See All Resources
Atorvastatin and Myocardial Extracellular Volume Expansion During Anthracycline-Based Chemotherapy
Go to Resource
Share:
Link is copied!
Originally Published:
June 12, 2025
Description
In the STOP-CA (Statins to Prevent the Cardiotoxicity From Anthracyclines) trial, atorvastatin preserved the left ventricular ejection fraction among patients with lymphoma treated with anthracyclines. The protective mechanisms are currently unclear. The aim of this study was to test the effect of atorvastatin on the anthracycline-associated increase in myocardial extracellular volume (ECV) using cardiac magnetic resonance imaging (MRI).
Join Tomas G. Neilan, MD (Harvard), and Vencel Juhasz, MD (Harvard), as they present Dr. Neilan's latest study from the STOP-CA trial providing mechanistic insight into the cardiovascular toxicity of anthracyclines.
